Literature DB >> 27582648

The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms.

Chelsie K Sievers1, Jeremy D Kratz2, Luke D Zurbriggen2, Noelle K LoConte3, Sam J Lubner3, Natalya Uboha3, Daniel Mulkerin3, Kristina A Matkowskyj4, Dustin A Deming5.   

Abstract

As treatment strategies for patients with colorectal cancer advance, there has now become an ever-increasing need for multidisciplinary teams to care for these patients. Recent investigations into the timing and duration of perioperative therapy, as well as, the rise of molecular profiling have led to more systemic chemotherapeutic options. The most efficacious use, in terms of timing and patient selection, of these therapies in the setting of modern operative and radiotherapy techniques requires the generation of care teams discussing cases at multidisciplinary conferences. This review highlights the role of multidisciplinary team conferences, advances in perioperative chemotherapy, current clinical biomarkers, and emerging therapeutic agents for molecular subtypes of metastatic colon cancer. As our understanding of relevant molecular subtypes increases and as data becomes available on treatment response, the treatment of colorectal cancer will become more precise and effective.

Entities:  

Keywords:  chemotherapy; colon cancer; rectal cancer

Year:  2016        PMID: 27582648      PMCID: PMC4991962          DOI: 10.1055/s-0036-1584292

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  51 in total

1.  Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

Authors:  Carsten Bokemeyer; Eric Van Cutsem; Philippe Rougier; Fortunato Ciardiello; Steffen Heeger; Michael Schlichting; Ilhan Celik; Claus-Henning Köhne
Journal:  Eur J Cancer       Date:  2012-03-23       Impact factor: 9.162

2.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

3.  Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.

Authors:  Bengt Glimelius; Olav Dahl; Björn Cedermark; Anders Jakobsen; Søren M Bentzen; Hans Starkhammar; Henrik Grönberg; Ragnar Hultborn; Maria Albertsson; Lars Påhlman; Kjell-Magne Tveit
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

4.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

5.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Authors:  Eric Van Cutsem; Heinz-Josef Lenz; Claus-Henning Köhne; Volker Heinemann; Sabine Tejpar; Ivan Melezínek; Frank Beier; Christopher Stroh; Philippe Rougier; J Han van Krieken; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

6.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

Authors:  Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto F Sobrero; Enrico Mini; Richard Greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; David Cunningham
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Improving patient survival with the colorectal cancer multi-disciplinary team.

Authors:  E MacDermid; G Hooton; M MacDonald; G McKay; D Grose; N Mohammed; C Porteous
Journal:  Colorectal Dis       Date:  2008-05-09       Impact factor: 3.788

8.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Victor E Velculescu
Journal:  Cell Cycle       Date:  2004-10-12       Impact factor: 4.534

9.  PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

Authors:  Hans Prenen; Jef De Schutter; Bart Jacobs; Wendy De Roock; Bart Biesmans; Bart Claes; Diether Lambrechts; Eric Van Cutsem; Sabine Tejpar
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

10.  MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?

Authors:  S Burton; G Brown; I R Daniels; A R Norman; B Mason; D Cunningham
Journal:  Br J Cancer       Date:  2006-02-13       Impact factor: 7.640

View more
  6 in total

1.  Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review.

Authors:  Rebecca A DeStefanis; Jeremy D Kratz; Philip B Emmerich; Dustin A Deming
Journal:  Curr Colorectal Cancer Rep       Date:  2019-03-20

Review 2.  Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.

Authors:  Mark Lawler; Deborah Alsina; Richard A Adams; Annie S Anderson; Gina Brown; Nicola S Fearnhead; Stephen W Fenwick; Stephen P Halloran; Daniel Hochhauser; Mark A Hull; Viktor H Koelzer; Angus G K McNair; Kevin J Monahan; Inke Näthke; Christine Norton; Marco R Novelli; Robert J C Steele; Anne L Thomas; Lisa M Wilde; Richard H Wilson; Ian Tomlinson
Journal:  Gut       Date:  2018-01       Impact factor: 23.059

3.  RBBP6 increases radioresistance and serves as a therapeutic target for preoperative radiotherapy in colorectal cancer.

Authors:  Chao Xiao; Yupeng Wang; Miao Zheng; Jian Chen; Guohe Song; Zhijie Zhou; Chongzhi Zhou; Xing Sun; Lin Zhong; Erxun Ding; Yi Zhang; Liu Yang; Gang Wu; Shifeng Xu; Hong Zhang; Xiaoliang Wang
Journal:  Cancer Sci       Date:  2018-03-10       Impact factor: 6.716

4.  Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation.

Authors:  Christoph Busemann; Andreas Jülich; Britta Buchhold; Vanessa Schmidt; Laila Schneidewind; Daniel Pink; Christian Andreas Schmidt; Thomas Neumann; William H Krüger
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-27       Impact factor: 4.553

5.  The inhibitory effect of TU-100 on hepatic stellate cell activation in the tumor microenvironment.

Authors:  Yuma Wada; Kazunori Tokuda; Yuji Morine; Shohei Okikawa; Shoko Yamashita; Tetsuya Ikemoto; Satoru Imura; Yu Saito; Shinichiro Yamada; Mitsuo Shimada
Journal:  Oncotarget       Date:  2020-12-08

Review 6.  Plant-Derived Bioactive Compounds in Colorectal Cancer: Insights from Combined Regimens with Conventional Chemotherapy to Overcome Drug-Resistance.

Authors:  Laura Ioana Gavrilas; Daniel Cruceriu; Andrei Mocan; Felicia Loghin; Doina Miere; Ovidiu Balacescu
Journal:  Biomedicines       Date:  2022-08-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.